Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Lilly pulls out of CNS portion of $960M collab with Rigel
Eli Lilly has pulled out of the CNS portion of a $960 million biobucks deal centered on Rigel’s RIPK1 inhibitors.
James Waldron
Nov 5, 2025 7:00am
Lilly inks $345M antibody pact with XtalPi subsidiary
Nov 5, 2025 7:00am
Prelude loses CMO, pauses SMARCA2 degraders, scores Incyte cash
Nov 4, 2025 9:40am
Boehringer's deal frenzy continues with $570M autoimmune pact
Nov 4, 2025 8:00am
Celltrion pens $744M pact for 2 preclinical autoimmune drugs
Nov 4, 2025 6:15am
Roche signs $2B pact to pilot Manifold's shuttles to the brain
Nov 3, 2025 8:45am
